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ABSTRACT
Objective: Diabetes mellitus (DM) is a major cause of disability, morbidity and mortality Worldwide. The objective of this study is to evaluate the 
pharmacoeconomic (PE) direct health-care cost in Type 2 diabetes with complications and diabetes alone: A cost of illness study.
Methods: A prospective observational study was conducted for 1 year at the care diabetes center, Warangal. The enrolled patients were followed and 
the information collected contains: Total direct costs, which include direct medical costs and direct nonmedical cost. The data observed was analyzed 
for the average cost incurred in treating the diabetic patient.
Results: The total average costs per diabetic patient without complications was Rs. 8695.7±1341, this includes the average direct medical cost 
Rs. 6366.50±561.12, the average laboratory cost Rs. 1368.84±64.8, the average direct nonmedical cost was Rs. 960.36±14.04 compared to those 
with DM complications, the total average cost was Rs. 12960.73±549.96 for macrovascular complications, Rs. 11039.11±265.36 for microvascular 
complications. To treat diabetes with comorbidities which include both micro and macro complications the total average cost was Rs. 16658.13±1393.44, 
the average direct medical cost was Rs. 14071.77±2884.68, the average laboratory cost Rs. 1628.04±51, the average direct nonmedical cost was 
Rs. 958.32±13.08. The costs were found to increase progressively with the increase in the number of complications. Costs also vary significantly across 
the types of complications.
Conclusion: Our study concludes that the cost of diabetes with complications resulted about 2 times higher than compared to diabetes alone.
Keywords: Cost analysis, Diabetes, Economics, Health care, Direct medical cost, Nonmedical cost.
INTRODUCTION
Diabetes mellitus (DM) is a common form that develops especially in 
adults and most often in obese individuals and that is characterized by 
hyperglycemia arising from impaired insulin utilization coupled with 
the body’s inability to compensate with increased insulin production 
called noninsulin-dependent DM. Obesity, stress, lack of exercise, diet 
rich in cholesterol and carbohydrates, aging and genetics are the causes 
of insulin resistance.
Complications of diabetes are to a large extent the consequence of 
macrovascular cardiovascular disease (CVD) and microvascular 
(retinopathy, neuropathy, and nephropathy) complications of the 
disease [1,2].
The objective of the study is to evaluate the health-care cost in diabetes 
and its comorbidities in out patients.
Global prevalence of Type 2 DM (T2DM) in the year 2000 among adults 
(≥20 years) was calculated to be 171 million and will rise to 366 million 
by 2030. In terms of country wise ranking of DM prevalence, India 
stands first, China second, Pakistan sixth, and Ukraine is at the bottom 
of the list [3].
As Indian population is 1.2 billion the economic effect of this increase 
in the diabetes population could cause distress to India. India is an 
emerging economy and will lose a billion dollars in National income 
due to diabetes, stroke, heart disease. Patients with diabetes use higher 
health-care resources [4]. The high cost is related to late diabetes 
complications, the money loss is due to lost man-days or lost economic 
opportunity [5]. The rise in prevalence of DM poses a major clinical, 
economic and social burden in India, which is being called as “the 
diabetic capital of the world.” The diabetic health-care cost is increasing 
throughout the World. Pharmacoeconomic (PE) analysis is one means 
of minimizing these expenditures [6].
PE is an established subdiscipline of health economics concerned with 
the estimation of pharmaceutical products in terms of their value of 
expenses. It is a “descriptive examination of the cost of drug therapy to 
the health-care system and also the society” [7].
PE evaluation consists of cost-minimization, cost-effectiveness, cost 
benefits, cost of illness, cost-utility, and cost-consequences [8]. Cost of 
illness is used to estimate the economic burden of disease. This method 
includes direct cost and indirect cost. The PE direct cost includes physician 
cost, therapy, travel cost, a hospital cost. We can calculate the incidence 
(life time cost) and prevalence (per year cost) through PE study [9].
METHODS
A prospective observational study was conducted in ambulatory 
patient’s care diabetes center, Warangal, Telangana, India. Patient’s data 
and cost details were collected from the bills for 1 year. The DM patients 
of age >18 years, both genders, patients who are diagnosed with DM 
and its mild comorbidities, were included in the study. In-patients, 
pregnant women, Type 1 diabetes patients, gestational diabetes patients 
and organ failure patients were excluded. The enrolled patients were 
followed during the study period and the relevant study data, including 
demographic details which contains, age, sex, education, occupation, 
past medical history, bills of both medical and laboratory were collected.
Cost of illness includes both direct and indirect cost, total direct costs 
consists of both direct medical and nonmedical costs. The direct medical 
cost includes the medical costs, cost of laboratory investigations and the 
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direct nonmedical costs include the transportation cost to the hospital. The 
costs of drugs, syringes, and any other invasive or noninvasive procedures 
along with laboratory tests were collected. All the relevant and necessary 
data were collected from a patient’s case sheet, bills, laboratory reports, 
interviewing patients or patient caretakers, or other relevant sources.
Mean and standard deviation was calculated for medical cost, laboratory 
cost, travel cost and total cost and the p value calculated  to compared 
male and female total cost.
RESULTS
A total of 550 patients were enrolled during the study period out of 
which most of the patients were males 276 (50.18%) than females 
274 (49.81%).
Diseases wise distribution of patients
Among the patients enrolled, the patients with DM, DM+HTN 
(hypertension), DM+CVD, DM+CVD+HTN, DM+peripheral 
neuropathy (PN), DM+HTN+CVD+PN are present. The diseases wise 
distribution of patients’ details was given in Table 1.
Table 1 shows that the patients with DM n=187(34%) are more followed 
by DM+HTN n=153 (27.8%).
Based on gender
Table 2 shown there is no differences between male Rs. 946±474.57 
and female Rs. 888.44±404.57 total cost, the p=0.085.
Occupation wise distribution
In occupation wise distribution, the average total cost was more in 
officers Rs. 1149.67 (20.58%) followed by house wives Rs. 928.66 
(16.62%), self-employees Rs. 913.68 (16.35%) is seen in (Fig. 1).
Per yearly cost
The total medical cost is high in patients with DM with both macro and 
micro complications (Rs. 14071.77±561.12) followed by DM+CVD+HTN 
(Rs. 10659.85±328.44), DM+PN (Rs. 8789.47±522.36), DM+HTN 
(Rs. 8779.31±1072.44), DM+CVD (Rs. 8576.75±1444.92), and DM 
(Rs. 6366.50±561.12).
The laboratory cost is high in DM+CVD (Rs. 1948.2±194.16), followed 
by DM with both macro and micro complications (Rs. 1628.04±51), 
DM+HTN (Rs. 1509±2.04), DM (Rs. 1368.84±64.8), DM+PN 
(Rs. 1320±86.64), DM+CVD+HTN (Rs. 1308.6±91.68).
The total travel cost was high in DM+CVD+HTN (Rs. 992.28±28.32) 
followed by DM (Rs. 960.36±14.04), DM with macro and micro 
complications (Rs. 958.32±13.08), DM+PN (Rs. 929.64±0.36), DM+HTN 
(Rs. 917.4±5.04), DM+CVD (Rs. 815.28±50.76).
The total cost was high in DM with macro and micro complications 
(Rs. 16658.13±1393.44), DM+HTN+CVD (Rs. 12960.73±549.96), 
DM+CVD (Rs. 11340.23±152.76), DM+HTN (Rs. 11205.71±184.08), 
DM+PN (Rs. 11039.11±265.36) and DM (Rs. 8695.7±1341) the above 
information is seen in Table 3.
As the complication increases the cost also increases. The cost burden 
of diabetes with two or more complications is more compared to 
diabetes with single complication and diabetes alone is seen in 
(Fig. 2).
DISCUSSION
This is the first study assessing the health-care direct cost of diabetes 
with comorbidities in the south Indian setup. Our study includes 
the treatment costs of diabetes alone and with comorbidities. The 
total cost was high in DM with macro and micro complications 
(Rs. 16658.13±1393.44), DM+HTN+CVD (Rs. 12960.73±549.96), 
DM+CVD (Rs. 11340.23±152.76), DM+HTN (Rs. 11205.71±184.08), 
DM+PN (Rs. 11039.11±265.36), and DM (Rs. 8695.7±1341).
The comparison with developing countries in Asia and Africa is more 
difficult due to lack of information on patient health-care expenditures 
for most of these countries. However, where data are available, they 
suggest as expected, much lower levels of expenditure. For example, the 
study assessing the treatment costs of diabetes in Karachi - Pakistan [10] 
estimated the annual mean treatment costs per DM patient to be 
$197 only. Another example is a study from Iran in 2009, which gave 
an annual cost figure of US $ 152 per DM patient [11]. Similarly, in 
Tunisia, an analysis in 1994 estimated an annual cost figure as low as 
US $ 117 [12], in Egypt costs were even lower and a study in Sudan 
showed direct costs to amount USD 175 per year [13]. Middle-income 
countries, such as those in Latin America and the Arabian region, tend 
to be in between Western and developing countries [14]. Of course, 
treatment costs exclude many intangible costs, which are also very 
high in developing countries. For example, the World Bank and WHO, 
together suggest that 80% of the annual intangible losses related to DM 
and its complications are incurred in developing countries.
The overall average, total health-care costs were found to be higher 
in males, i.e., Rs. 946.89 than females, i.e., Rs. 888.44 and it was found 
to be higher in the age group of 80-85 years Rs. 1224.98, 74-79 years 
Rs. 1121.73 followed by 68-73 years Rs. 1028.10 this might be due to 
Table 1: Diseases wise distribution of patients
Diagnosis ICD code Number of patients (%)
DM E11 187 (34)
DM+HTN I15.2 153 (27.8)
DM+CVD I70.9 17 (3.09)
DM+CVD+HTN E11 42 (7.6)
DM+PN E11.4 70 (12.7)
DM+HTN+CVD+PN E11 81 (14.7)
DM: Diabetes mellitus, HTN: Hypertension, CVD: Cardiovascular disease, 
PN: Peripheral neuropathy
Table 2: Gender wise distribution based on the total cost of the 
patients
Gender Total cost p
Female Rs. 888.44±404.57 0.085
Male Rs. 946.89±474.57
Table 3: Cost burden per year in patients with diabetes alone and its complication
Diagnosis Mean±SD
Medical cost (INR) Laboratory cost (INR) Travel cost (INR) Total cost (INR)
DM 6366.50±561.12 1368.84±64.8 960.36±14.04 8695.7±1341
DM+HTN 8779.31±1072.44 1509±2.04 917.4±5.04 11205.71±184.08
DM+CVD 8576.75±1444.92 1948.2±194.16 815.28±50.76 11340.23±152.76
DM+HTN+CVD 10659.85±328.44 1308.6±91.68 992.28±28.32 12960.73±549.96
DM+PN 8789.47±522.36 1320±86.64 929.64±0.36 11039.11±265.36
DM+PN+HTN+CVD 14071.77±2884.68 1628.04±51 958.32±13.08 16658.13±1393.44
DM: Diabetes mellitus, HTN: Hypertension, CVD: Cardiovascular disease, PN: Peripheral neuropathy, SD: Standard deviation
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increased number of comorbidities, similar results were found in the 
studies of Hogan et al., 2003 and Henriksson et al., 2000 [15,16].
The overall average health-care costs were found to be 
higher in the patients with micro and macro complications 
Rs. 1233.1±116.12 (21.11%) followed by only macro with single 
comorbidity DM+CVA Rs. 945.02±12.73 (16.18%) and DM+HTN 
Rs. 939.18±15.34 (16.07%) followed by only micro DM+PN 
Rs. 924.05±22.11 (15.82%). The results of this study showed increased 
total health-care cost with increased number of complications.
Out of 550 patients, most of the patients were house wives followed by 
farmers, whereas overall health-care costs were higher in officers with 
Rs. 1149.67 (20.58%) followed by house wives Rs. 928.66 (16.62%) 
and self employees Rs. 913.68 (16.35%) this might be due their busy 
schedules with the work. The average overall medical cost was high in 
patients taking insulin, i.e., Rs. 1276.44 compared to patients on oral 
hypoglycemic agents, i.e., Rs. 117.58.
Hospital monthly visits laboratory costs and travel cost accounts for 
the largest part of diabetes cost and for patients who have developed 
late macro complications will greatly affect the cost which includes 
cost for any surgery. Furthermore, most diabetics on oral hypoglycemic 
agents receive insulin soon after hospital admission for developing 
complications and these further increases the costs.
CONCLUSION
Diabetes with complications resulted in double the cost compared to 
diabetes alone, therefore, the burden of diabetes and its complications 
was significant for an individual, much of this cost associated with the 
disease is preventable through diet restriction and aerobic exercise, 
to reduce the prevalence of diabetes and its complications in mind. 
By keeping the burden of the disease on individuals on the society, the 
health-care policy makers should give importance to initiatives like 
preventing the disease prevalence and counseling diabetes patients 
should be done continuously to control the advancement of the disease 
and its complications. To avoid increased medical cost, early detection 
of complications through appropriate screening is important, such 
as adequate control of blood sugar, blood pressure, cholesterol with 
proper diet restrictions, and some lifestyle modification is important.
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Fig. 1: Total cost in various occupations of patient
Fig. 2: Disease vs. total cost burden
